These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11156732)

  • 1. The use of bivalirudin in patients with renal impairment.
    Robson R
    J Invasive Cardiol; 2000 Dec; 12 Suppl F():33F-6. PubMed ID: 11156732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bivalirudin: a direct thrombin inhibitor.
    Gladwell TD
    Clin Ther; 2002 Jan; 24(1):38-58. PubMed ID: 11833835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
    Carswell CI; Plosker GL
    Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.
    Robson R; White H; Aylward P; Frampton C
    Clin Pharmacol Ther; 2002 Jun; 71(6):433-9. PubMed ID: 12087346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures.
    Chew DP
    Hamostaseologie; 2002 Aug; 22(3):60-6. PubMed ID: 12215763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.
    Kiser TH; Burch JC; Klem PM; Hassell KL
    Pharmacotherapy; 2008 Sep; 28(9):1115-24. PubMed ID: 18752382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia.
    Runyan CL; Cabral KP; Riker RR; Redding D; May T; Seder DB; Savic M; Hedlund J; Abramson S; Fraser GL
    Pharmacotherapy; 2011 Sep; 31(9):850-6. PubMed ID: 21923585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of bivalirudin during percutaneous coronary interventions in patients with abnormal renal function.
    Roguin A; Steinberg BA; Watkins SP; Resar JR
    Int J Cardiovasc Intervent; 2005; 7(2):88-92. PubMed ID: 16093217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.
    Taylor LA; Mauro VF
    Ann Pharmacother; 2012 Jan; 46(1):35-41. PubMed ID: 22170973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia.
    Tsu LV; Dager WE
    Ann Pharmacother; 2011 Oct; 45(10):1185-92. PubMed ID: 21881032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalirudin: a review of the pharmacology and clinical application.
    Van De Car DA; Rao SV; Ohman EM
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1673-81. PubMed ID: 21108549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct thrombin inhibitors.
    Simonton C
    J Invasive Cardiol; 2004 Jul; 16(7 Suppl):17S-23S. PubMed ID: 23573567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials.
    Chew DP; Bhatt DL; Kimball W; Henry TD; Berger P; McCullough PA; Feit F; Bittl JA; Lincoff AM
    Am J Cardiol; 2003 Oct; 92(8):919-23. PubMed ID: 14556866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
    Campbell KR; Mahaffey KW; Lewis BE; Weitz JI; Berkowitz SD; Ohman EM; Califf RM
    J Invasive Cardiol; 2000 Dec; 12 Suppl F():14F-9. PubMed ID: 11156729
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty.
    Burchenal JE; Marks DS; Tift Mann J; Schweiger MJ; Rothman MT; Ganz P; Adelman B; Bittl JA
    Am J Cardiol; 1998 Aug; 82(4):511-5. PubMed ID: 9723642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalirudin: a review.
    Warkentin TE; Koster A
    Expert Opin Pharmacother; 2005 Jul; 6(8):1349-71. PubMed ID: 16013985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial results with hirudin and bivalirudin for acute coronary artery syndromes.
    Bates ER
    Semin Thromb Hemost; 1997; 23(6):575-81. PubMed ID: 9469633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and clinical use of bivalirudin.
    Sciulli TM; Mauro VF
    Ann Pharmacother; 2002 Jun; 36(6):1028-41. PubMed ID: 12022907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials of Hirulog in patients undergoing high-risk percutaneous transluminal coronary angioplasty.
    Bittl JA
    Coron Artery Dis; 1996 Jun; 7(6):449-54. PubMed ID: 8889360
    [No Abstract]   [Full Text] [Related]  

  • 20. A second look at bivalirudin.
    Antman EM; Braunwald E
    Am Heart J; 2001 Dec; 142(6):929-31. PubMed ID: 11717592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.